Search
Results
showing 1-10 of 2303
The US HIV Cure Academy
August 2026
The US HIV Cure Academy connects people affected by HIV with leading researchers to explore the latest HIV cure strategies and equip them with the skills needed to prepare their communities to engage in HIV cure research.
Global Health Watch: Legacies of Parton & Goosby, expiring global health funds, Jeremy Lewin’s move, Ebola funding & vaccine R&D
August 2026
This week, the global health community lost a powerful, if unlikely, champion in Dolly Parton. Longtime leader Eric Goosby, who served as the US Global AIDS Coordinator and led the President’s Emergency Plan for AIDS Relief (PEPFAR) from 2009 to 2013 under President Barack Obama, officially retired this week. Also this week, members of the US Congress demanded that the Administration release billions in congressionally-appropriated global health funding; another leadership change is underway at the Department of State; and in the DRC, the Ebola response is making progress even as inadequate funding threatens efforts.
Lenacapavir Regulatory Approval
August 2026
Regulatory approvals, pending decisions, and appeals as of August 2026.
From Research to Access: The Community Statement from the Global Community Advisory Group (GCAG) on the Future of Alima (Alimatravir) for HIV Prevention
August 2026
The EXPrESSIVE-10 Global Community Advisory Group (GCAG) released a statement on the future of alimatravir and HIV prevention. The statement reflects community perspectives and priorities around prevention choice, meaningful community engagement, equitable access, and ensuring that communities have a voice as research progresses toward potential introduction. As the GCAG writes, “The test is now whether early planning can translate into faster, more equitable action. An access plan is valuable not because it is announced, but because it creates a pathway that can be tracked, challenged, and delivered.”
PxWire Volume 16, Issue 3
August 2026
This issue of PxWire showcases updates presented at the AIDS 2026 conference in Rio de Janeiro, Brazil. As the field continues to grapple with the impact of PEPFAR funding cuts on HIV services, amfAR shared their latest analysis from the PEPFAR Pulse Study. AVAC’s latest infographic unpacks the current status of generic licensing agreements for long-acting PrEP products. Recent trials on long-acting treatment and broadly neutralizing antibodies (bNAbs) for prevention were also shared at the conference. A new weekly pill for HIV treatment demonstrated non-inferiority, while a combination of two bNAbs did not provide protection from HIV. Both results provided important insights and implications for the current status of the HIV prevention and treatment pipelines.
ISL/LEN Phase 3 Development Program
August 2026
At AIDS 2026, Merck and Gilead presented detailed results from the Phase 3 ISLEND trials, showing that an investigational weekly oral single-tablet treatment regimen combining islatravir (ISL) from Merck/MSD and lenacapavir (LEN) from Gilead sustained viral suppression as effectively as daily oral antiretroviral therapy (ART) at week 48; the studies will continue to week 96. This infographic features data from Gilead’s AIDS 2026 presentations on ISLEND-1 and ISLEND-2 trials.
Percentage Change in PEPFAR Prevention Expenditures, FY24 to FY25
August 2026
This infographic, with data featured in amfAR’s PEPFAR Pulse study, examines the percentage change in PEPFAR prevention expenditures from FY24 to FY25. Significant challenges persist in the wake of cuts to PEPFAR programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services with fewer resources.
Global Health Watch: NIH reopens South Africa Research Funding; DRC Ebola Strains Outbreak Response; WHO + FDA Leadership Shifts
August 2026
The US National Institutes of Health (NIH) lifted research funding restrictions on South Africa; the DRC’s Ebola outbreak grows, exposing the consequences of weakened outbreak-response systems; and leadership changes at the World Health Organization (WHO) and the US Food and Drug Administration (FDA) raise questions about the future of global health decision-making.
The Latest Resources from AVAC: Advancing Science, Expanding Access
August 2026
Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, developments and takeaways from AVAC and explores what’s needed and what’s next to ensure the latest innovations move beyond headlines and into the hands of the communities that need them most.
EXPrESSIVE Phase III Program Countries of Alimatravir
August 2026
Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase III trials at IAS 2025 in Kigali. Alimatravir (AMI) was found to be safe and well-tolerated in Phase II clinical trials.
showing 1-10 of 2303